

PHARMACEUTICAL 2023

NANOVIRICIDES INC. Rank 33 of 446







RealRate

PHARMACEUTICAL 2023

NANOVIRICIDES INC. Rank 33 of 446

The relative strengths and weaknesses of NANOVIRICIDES INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NANOVIRICIDES INC. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 68% points. The greatest weakness of NANOVIRICIDES INC. is the variable Other Revenues, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 264%, being 221% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	14,416
Cost of Goods Sold	0
Intangible Assets	342
Liabilities, Current	413
Liabilities, Non-Current	0
Other Assets	42
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	6.7
Other Revenues	0
Property and Equipment	8,694
Research and Development	5,785
Selling, General and Administrative Expense	2,329

Output Variable	Value in 1000 USD
Assets	23,495
Liabilities	413
Expenses	8,114
Revenues	0
Stockholders Equity	23,082
Net Income	-8,107
Comprehensive Net Income	-8,107
Economic Capital Ratio	264%

